129 related articles for article (PubMed ID: 37698411)
1. Treatment Outcome in Head and Neck Cancer With Distant Metastasis at Initial Diagnosis.
Omata J; Ueki Y; Takahashi Y; Tanaka R; Yokoyama Y; Takahashi T; Shodo R; Yamazaki K; Togashi T; Matsuyama H; Takahashi N; Okabe R; Horii A
Laryngoscope; 2024 Apr; 134(4):1679-1686. PubMed ID: 37698411
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma.
Chen TH; Pan YY; Lee TL; Wang LW; Tai SK; Chu PY; Lo WL; Wu CH; Yang MH; Chang PM
BMC Cancer; 2022 Dec; 22(1):1336. PubMed ID: 36539738
[TBL] [Abstract][Full Text] [Related]
3. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.
Leeman JE; Li JG; Pei X; Venigalla P; Zumsteg ZS; Katsoulakis E; Lupovitch E; McBride SM; Tsai CJ; Boyle JO; Roman BR; Morris LGT; Dunn LA; Sherman EJ; Lee NY; Riaz N
JAMA Oncol; 2017 Nov; 3(11):1487-1494. PubMed ID: 28542679
[TBL] [Abstract][Full Text] [Related]
4. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
5. Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols.
Haring CT; Kana LA; Dermody SM; Brummel C; McHugh JB; Casper KA; Chinn SB; Malloy KM; Mierzwa M; Prince MEP; Rosko AJ; Shah J; Stucken CL; Shuman AG; Brenner JC; Spector ME; Worden FP; Swiecicki PL
Cancer; 2023 Sep; 129(18):2817-2827. PubMed ID: 37162461
[TBL] [Abstract][Full Text] [Related]
6. Incurable locoregional disease is a strong poor prognostic factor in recurrent or metastatic squamous cell carcinoma of the head and neck.
Nishimura A; Yokota T; Hamauchi S; Onozawa Y; Shirasu H; Kawabata T; Ogawa H; Onoe T; Iida Y; Mukaigawa T; Yasui H
Int J Clin Oncol; 2021 Oct; 26(10):1822-1830. PubMed ID: 34152533
[TBL] [Abstract][Full Text] [Related]
7. De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?
Lorini L; Gili R; Salvestrini V; Morelli I; Smussi D; Petrelli F; Bonomo P; Bossi P
Oral Oncol; 2024 May; 152():106768. PubMed ID: 38552469
[TBL] [Abstract][Full Text] [Related]
8. Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in head and neck squamous cell carcinoma (R/M-HNSCC) patients treated with first line platinum-based chemotherapy.
Pitakpaiboonkul P; Jiarpinitnun C; Pattaranutaporn P; Ngamphaiboon N
Cancer Med; 2024 Feb; 13(4):e7047. PubMed ID: 38457195
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for long-term survival in head and neck squamous cell carcinoma patients with distant metastasis after initial definitive treatment.
Kang HS; Roh JL; Kim MJ; Cho KJ; Lee SW; Kim SB; Choi SH; Nam SY; Kim SY
J Cancer Res Clin Oncol; 2016 Jan; 142(1):295-304. PubMed ID: 26341665
[TBL] [Abstract][Full Text] [Related]
10. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
Park JH; Chun SH; Lee YG; Chang H; Lee KW; Kim HR; Shin SH; An HJ; Lee KE; Hwang IG; Ahn MJ; Kim SB; Keam B
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3359-3369. PubMed ID: 32671504
[TBL] [Abstract][Full Text] [Related]
11. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
[TBL] [Abstract][Full Text] [Related]
12. A novel nomogram and risk classification system for predicting overall survival in head and neck squamous cell cancer with distant metastasis at initial diagnosis.
Zhu RQ; Zhang YM; Luo XY; Shen WY; Zhu HY
Eur Arch Otorhinolaryngol; 2023 Mar; 280(3):1467-1478. PubMed ID: 36316576
[TBL] [Abstract][Full Text] [Related]
13. Prognostic model for overall survival of head and neck cancer patients in the palliative phase.
Hoesseini A; Sewnaik A; van den Besselaar BN; Zhang J; van Leeuwen N; Hardillo JA; Baatenburg de Jong RJ; Offerman MPJ
BMC Palliat Care; 2024 Feb; 23(1):54. PubMed ID: 38395897
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
15. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of clinical and
Cho JK; Hyun SH; Choi JY; Choi N; Kim MJ; Lee SH; Baek KH; Jeong HS
J Surg Oncol; 2016 Dec; 114(7):888-894. PubMed ID: 27546387
[TBL] [Abstract][Full Text] [Related]
17. Impact of locoregional irradiation in patients with upfront metastatic head and neck squamous cell carcinoma.
Rambeau A; Bastit V; Thureau S; Thariat J; Moldovan C; Roge M; Babin E; Gery B; Di Fiore F; Florescu C; Clatot F
Oral Oncol; 2019 Jun; 93():46-51. PubMed ID: 31109695
[TBL] [Abstract][Full Text] [Related]
18. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
20. Are immune checkpoint inhibitors ineffective in treating patients with head and neck squamous cell carcinoma aged 75 years or Older? A Meta-Analysis.
Zhang S; Zheng M; Tian H; Liu W; Feng Z; Xing S; Han F
Oral Oncol; 2024 Jan; 148():106632. PubMed ID: 38039875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
